The German molecular diagnostics and reagents firm said it has converted more than 80 percent of a planned total of 180 products to the new IVDR regulatory framework.

GoodBiome™ Foods are functional foods containing a probiotic (Bacillus subtilis HU58™) and prebiotics (mainly inulin). Their effects on the human gut microbiota were assessed using ex vivo SIFR® technology, which has been validated to provide clinically predictive insights. GoodBio …

Clostridioides difficile may constitute a small part of normal gut microbiota in humans without causing any symptoms, but an uncontrolled growth common to hospitalized patients can cause Clostridioides difficile infection (CDI) leading to severe colonic symptoms. As the bacteria are attaining resist …

Antimicrobial resistance poses a major threat to global health and food security and is primarily driven by antimicrobial use in human and veterinary medicine. Understanding its epidemiology at farm level is crucial for effective control measures. Despite the significant reduction in antibiotic use …

Toxins TcdA and TcdB are the main virulence factors of Clostridioides difficile, a leading cause of hospital-acquired diarrhea. Despite their importance, there is a significant knowledge gap of druggable targets for inhibiting toxin production. To address this, we screened non-antibiotic phytochemic …

HA-CDI is associated with a higher risk of anastomotic leak after oncological colorectal surgery, while asymptomatic CDC do not have higher morbidity and may be operated electively, under standard CD treatment.

Global Clostridium Diagnostics Market is valued at approximately USD 838.05 million in 2022 and is anticipated to grow with a healthy growth rate of more than 7.10% over the forecast period 2023-2030.

C. diff survivor and Peggy Lillis Foundation Board Member Maryann Webb discusses how her experience with the infection encouraged her to advocate for patients who are struggling to advocate for themselves.

The Business Research Company recently released a comprehensive report on the Global Difficile Associated Diarrhea Treatment Market Size and Trends Analysis with Forecast 2024 2033 This latest market research report offers a wealth of valuable insights and data including global ...

Acurx reports ibezapolstat's positive microbiome effects and Anthrax activity

• One hundred seven patients with cystic fibrosis (CF) and 54 other patients with risk factors for Clostridium difficile–associated disease were entered into a bacteriologic study to compare the rate of recovery of C difficile and cytotoxin in feces with occurrence of diarrhea and to investigate...

Clostridioides difficile, a gram-positive, toxin-producing, spore-forming anaerobe, is a major cause of antibiotic-associated diarrhoea. The bacterium's intrinsic drug resistance limits current treatment options to fidaxomicin and vancomycin for initial episodes, with anti-toxin B monoclonal antibod …

Study halted due to ineffective results, but the findings still provide valuable insights for future research and improve treatment strategies for those affected by CDI.

Hello, it's Ashleigh coming to you from New York this week where the city is flooded with world leaders for the UN General Assembly. On Thursday the buzz of attention shifted to the “silent pandemic” of antimicrobial resistance. But first...

Fecal microbiota-based therapies are becoming more prevalent in the management of Clostridioides difficile infection.

More commonly known as C. diff, Clostridioides difficile is a microbe known to cause diarrhoea, colitis and other bowel complications

Publisher Correction: Virulence factors, antibiotic susceptibility and sequence type distribution of hospital-associated Clostridioides difficile isolates in Israel, 2020-2022

The diagnosis of Clostridioides difficile infection (CDI) in the pediatric population is complicated by the high prevalence of asymptomatic colonization, particularly in infants. Many laboratory diagnostic methods are available, but there continues to be controversy over the optimal laborator …

A preventive strategy based on systematic LTBI screening and moxifloxacin treatment before LT in positive cases appears safe and effective in preventing the development of tuberculosis in LT recipients. However, our findings are limited by a small sample size; thus, larger studies are required to va …

Which trials do we need? Fidaxomicin plus either intravenous metronidazole or tigecycline versus vancomycin plus either intravenous metronidazole or tigecycline for fulminant Clostridioides difficile infection

The far UV-C light technology could potentially be useful for automated decontamination of air and surfaces in bathrooms in healthcare and community settings.

Dublin, Sept. 30, 2024 (GLOBE NEWSWIRE) -- The

Our findings are consistent with the previous studies that suggested the incubation period for CDI is typically less than 1 week and is less than 2 weeks in most cases.

The fact that our caFMT compared similarly to the imported caFMT was viewed as a success in terms of quality assurance. Our caFMT had a slightly lower success rates compared to data from other studies, but could be affected by several other factors than our FMT-production methods. A lower success ra …

Study finds underutilization of fidaxomicin, a recommended treatment for C. diff infection, despite increased use in hospitals.

Mainly performed within a rapid diagnostic tests company, a lateral flow (LF) system using gold nanoparticles (AuNPs) as transducers is presented able to detect three bacteria of interest, of relevance for antimicrobial resistance (AMR): Clostridioides difficile, methicillin-resistant Staphylococcus …

Our study suggests that the differing gut microbiota profiles in pediatric CDI patients may contribute to disease recurrence by modulating SCFA concentrations and bile acid profiles. The gut microbiota and metabolite signatures may be used to predict disease recurrence in children with CDI.

Clostridioides difficile infection (CDI) is a health crisis comprising a majority of healthcare-associated infections and is now being seen in the community. Persistent dysbiosis despite treatment with standard-of-care antibiotics increases risk of recurrent infections. Fecal microbiota trans …

Maryann Webb’s harrowing, personal experience with C diff, along with her professional work with federal agencies has prepared her for a life in advocacy with the Peggy Lillis Foundation. She wants to see the fecal microbiota transplant become more accessible and is working with Congress to make the infection a notifiable infectious disease.

Clostridioides difficile, a gram-positive, toxin-producing, spore-forming anaerobe, is a major cause of antibiotic-associated diarrhoea. The bacterium's intrinsic drug resistance limits current treatment options to fidaxomicin and vancomycin for initial episodes, with anti-toxin B monoclonal antibod …